Cadrenal Therapeutics, Inc.

Analysis for Ticker: CVKD

Cadrenal Therapeutics Inc is a biofarmaceutical company that claims to develop heart and kidney therapies, but its current mathematical reality is a disaster designed to consume retail capital. The company is burning through its final 4,0$ million in cash, which its own auditors officially warned will not last another twelve months. The most shocking part of the current collapse is their plan to pay for fifty hospitals around the world just to find one hundred twenty people for a drug that already failed its last clinical test. This means you are paying for the lights, the doctors, and the paperwork at fifty different locations just to find barely two point four patients per hospital until 2029. This global infrastructure will consume cash much faster than they can raise it, creating a nightmare where the company must print new shares just to keep empty waiting rooms open.